Conferences - Results from #860

Viewing 861-880 of 11869 articles

EAU 2024: Efficacy of Intravesical Nadofaragene Firadenovec-Vncg for Patients with BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer: 36-Month Follow-up from a Phase 3 Trial

EAU 2024: Efficacy and Safety of Darolutamide in Combination with ADT and Docetaxel in European Patients from the Phase 3 ARASENS Trial

EAU 2024: First Safety and Efficacy Results of the TAR-210 Erdafitinib Intravesical Delivery System in Patients with Non–muscle-Invasive Bladder Cancer with Select FGFR Alterations

EAU 2024: Impact of Disease Volume on Survival Efficacy of Triplet Therapy for Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review, Meta-analysis, and Network Meta-analysis

EAU 2024: Familial Prostate Cancer: Does It Influence the Screening and Management?

EAU 2024: PARP Inhibitor Plus Androgen Receptor Pathway Inhibitor Combinations for 1st Line mCRPC: A Systematic Review and Meta-Analysis

EAU 2024: Comparison of Biparametric and Multiparametric MRI for Prostate Cancer Detection: The PRIME Study

EAU 2024: PEACE V – Salvage Treatment of OligoRecurrent Nodal Prostate Cancer Metastases (STORM): 24-Months Toxicity Results of a Randomized Phase II Trial

Oral Vaccine for UTI Is Potential Alternative to Antibiotics, Finds 9-Year Study

EAU 2024: Early Oncological Outcomes Following Radical Prostatectomy of Patients with Pelvic Lymph Node-Positive Prostate Cancer at Preoperative PSMA PET/CT

EAU 2024: Neoadjuvant Pamiparib plus Abiraterone and ADT for High-Risk/very High-Risk Localized Prostate Cancer: Results of a Prospective Study

EAU 2024: Challenging EAU Guidelines on Prostate Cancer Risk Definition in the Screening Setting: Insights from the PROBASE Trial

EAU 2024: Results from SunRISe-1 in Patients with BCG-Unresponsive High-Risk Non–muscle-Invasive Bladder Cancer Receiving TAR-200 Monotherapy

EAU 2024: Negative Staging PSMA in High-Risk Disease: Can We Skip Extended PLND? the Guidelines' View

EAU 2024: Results from the First Screening Round of the ProScreen Screening Trial with PSA, Kallikrein Panel and MRI

EAU 2024: Which Future for Immunotherapy in Localized Kidney Cancer?

EAU 2024: Rapid Fire Debate 6: Patient with Non-Invasive, High Grade Upper Tract Disease in Setting of Prior Radical Cystectomy – What Is Optimal Management? What If GFR ~ 50 Instead of 80?

EAU 2024: Trial in Progress: SunRISe-3: TAR-200 plus Cetrelimab or TAR-200 Versus Intravesical BCG in Patients with BCG-Naive High-Risk Non–muscle-Invasive Bladder Cancer

EAU 2024: Validation of FGFR Screening by Uromonitor® and Therascreen in FFPE Tissue in Bladder Cancer in the Context of the Clinical-Pathological Real-World Registry Study "Bladder BRIDGister"

EAU 2024: Rapid Fire Debate 5: The Age-Old Debate – What Is the Best Treatment – Oncological and QoL – for Young Healthy Patient with MIBC? What About Health Care Related Costs?

39
40
41
42
43
44
45
46
47
48